Analyst Reco. Atai Life Sciences N.V.

Equities

ATAI

NL0015000DX5

Real-time Estimate Cboe BZX Other stock markets 03:08:39 2024-04-26 pm EDT			5-day change	1st Jan Change
1.925 ^USD	+4.62%		+4.32%	+36.88%

Apr. 24	Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech?s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression	CI
Apr. 17	Clarify Pharma to change name to File Forge Technology	AN

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Atai Life Sciences Shares Rise Following Maxim Upgrade	Apr. 03	MT
Maxim Upgrades Atai Life Sciences to Buy From Hold, Price Target is $6	Apr. 03	MT
HC Wainwright Cuts Atai Life Sciences Price Target to $15 From $20, Maintains Buy Rating	Apr. 03	MT
Berenberg Bank Adjusts Atai Life Sciences Price Target to $11 From $18, Maintains Buy Rating	23-03-29	MT
Credit Suisse Lowers Atai Life Sciences' PT to $9 From $11, Updates Model After Announced Workforce Reduction; Keeps Outperform Rating	23-03-07	MT
HC Wainwright Adjusts Price Target on Atai Life Sciences to $20 From $50, Maintains Buy Rating	23-01-19	MT
EF Hutton Adjusts Atai Life Sciences Price Target to $15 From $23, Maintains Buy Rating	23-01-06	MT
Berenberg Bank Resumes Coverage on Atai Life Sciences With Buy Rating, $18 Price Target	22-12-21	MT
EF Hutton Initiates Atai Life Sciences at Buy With $23 Price Target	22-12-16	MT
Berenberg US CEO Conference	22-11-01	FA
Loop Capital Initiates Atai Life Sciences at Buy With $18 Price Target	22-11-01	MT
Citigroup Adjusts Price Target on Atai Life Sciences to $20 From $22, Reiterates Buy Rating	22-09-01	MT
Berenberg Bank Suspends Coverage of 25 Companies in Consumer Discretionary, Healthcare, Industrial Tech, and Software Sectors	22-07-01	MT
Citigroup Adjusts Price Target on Atai Life Sciences to $22 From $26, Reiterates Buy Rating	22-05-17	MT
RBC Capital Adjusts Atai Life Sciences Price Target to $9 From $12, Maintains Sector Perform - Speculative Risk Rating	22-03-31	MT
Maxim Group Adjusts Atai Life Sciences Price Target to $12 From $25, Maintains Buy Rating	22-02-02	MT
RBC Cuts Price Target on Atai Life Sciences to $12 From $17, Maintains Sector Perform Rating, Speculative Risk Qualifier	22-01-06	MT
Berenberg European Conference	21-12-05	FA
Maxim Group Initiates Coverage on Atai Life Sciences With Buy Rating, $25 Price Target	21-11-30	MT
HC Wainwright Adjusts Atai Life Sciences to $50 From $40, Reiterates Buy Rating	21-11-22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Atai Life Sciences N.V.

Equities

ATAI

NL0015000DX5

Analyst Reco.

Filters